老司机福利精品日韩AV,成人影院无码AV一区二区,亚洲AV日韩第一第二社区,极品露脸日韩AV

新加坡频祝，2024年5月23日 – 藥明康德今日宣布其位于新加坡的研發(fā)及生產(chǎn)基地正式開工建設(shè)凑魔。這是繼2022年宣布設(shè)立新加坡基地后又一個重要里程碑史飞，標志著公司在CRDMO賦能平臺建設(shè)進程中又邁出了堅實的一步则沃，助力全球客戶加速醫(yī)藥創(chuàng)新龄广、造福病患卑绢。

藥明康德新加坡基地位于大士（Tuas）生物醫(yī)藥園讼舰，占地50英畝，由裕廊集團（JTC）負責總體設(shè)計建設(shè)阐祭。新基地滿負荷運轉(zhuǎn)時將有7個研發(fā)生產(chǎn)車間柄童，為小分子、寡核苷酸搬挡、多肽及復雜的合成偶聯(lián)藥物提供原料藥研發(fā)和生產(chǎn)服務免趋。通過應用行業(yè)領(lǐng)先的綠色化學技術(shù)，新加坡基地將致力于提升行業(yè)實踐標準术拇，促進當?shù)厣鐓^(qū)的可持續(xù)發(fā)展蔬透。

作為藥明康德全球研發(fā)和生產(chǎn)網(wǎng)絡(luò)的重要組成部分，新加坡基地將與公司在亞洲耻债、歐洲和北美的各個基地緊密協(xié)同，進一步加強公司CRDMO賦能平臺的靈活性和規(guī)模疤信，為客戶提供從藥物發(fā)現(xiàn)到商業(yè)化生產(chǎn)的高效解決方案吩猴。

新加坡經(jīng)濟發(fā)展局主席方章文先生表示：“藥明康德在新加坡設(shè)立CRDMO基地，標志著該公司正式加入新加坡生物醫(yī)學生態(tài)圈口猜，為本地行業(yè)的蓬勃發(fā)展注入新能量负溪。新基地將在本地組建一支規(guī)耐复В可觀的研發(fā)及生產(chǎn)團隊，推動突破性療法的研發(fā)川抡。新加坡致力于與生物醫(yī)學行業(yè)伙伴攜手合作辐真，為全球各地的患者帶來創(chuàng)新治療方案⊙碌蹋”

“我們很高興看到這一長期規(guī)劃的基地在新加坡正式動工侍咱。感謝當?shù)睾献骰锇榈闹С郑屵@個項目取得令人矚目的進展密幔⌒ǜ”藥明康德聯(lián)席首席執(zhí)行官陳民章博士表示：“公司不斷建能力、擴規(guī)模胯甩，為客戶提供高質(zhì)量的服務昧廷，持續(xù)滿足行業(yè)日益變化的需求，新加坡基地將幫助我們更好地服務本地及全球客戶偎箫∫π埽”

“藥明康德的愿景是‘讓天下沒有難做的藥，難治的病’莱检『熳睿”藥明康德董事長兼首席執(zhí)行官李革博士表示：“我們很榮幸能與新加坡志同道合的伙伴攜手，共同實現(xiàn)這一偉大夢想墅萌。藥明康德將持續(xù)加強能力和規(guī)模建設(shè)筑卑，賦能客戶加速研發(fā)進程，推動更多新藥肄酬、好藥早日問世陈售，造福全球病患∠院叮”

新加坡基地計劃于2027年投入運營伦颠，整體工程建設(shè)將會分階段推進。全面竣工后件塌，新基地預計將創(chuàng)造1600個就業(yè)崗位侮杆。

關(guān)于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）為全球醫(yī)藥及生命科學行業(yè)提供一體化、端到端的新藥研發(fā)和生產(chǎn)服務漱凝，在亞洲疮蹦、歐洲、北美等地均設(shè)有運營基地茸炒。藥明康德通過獨特的“CRDMO”和“CTDMO”業(yè)務模式愕乎，不斷降低研發(fā)門檻，助力客戶提升研發(fā)效率壁公，為患者帶來更多突破性的治療方案感论，服務范圍涵蓋化學藥研發(fā)和生產(chǎn)绅项、生物學研究、臨床前測試和臨床試驗研發(fā)比肄、精準醫(yī)療研發(fā)快耿、測試和生產(chǎn)等領(lǐng)域。2023年芳绩，藥明康德連續(xù)第三年被MSCI評為ESG（環(huán)境掀亥、社會及管治）AA級。目前示括，公司的賦能平臺正承載著來自全球30多個國家的6,000多家合作伙伴的研發(fā)創(chuàng)新項目铺浇，致力于將更多新藥、好藥帶給全球病患叛始，早日實現(xiàn)“讓天下沒有難做的藥祷消，難治的病”的愿景。

WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers

SINGAPORE, May 23, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced the groundbreaking of its new R&D and manufacturing site in Singapore. This milestone, following the announcement of the new site in 2022, marks another step forward in WuXi AppTec’s mission to continuously enhance its CRDMO enabling platform to better support customers worldwide in advancing healthcare treatments and innovations.

The new 50-acre Singapore site is located in the thriving Tuas Biomedical Park with the master planning and development by JTC to encompass a total of seven plants at its full capacity, providing active pharmaceutical ingredient (API) R&D and manufacturing services for small molecules, oligonucleotides, peptides, and complex synthetic conjugates. Embracing industry-leading green chemistry technology initiatives, this new site is dedicated to improving industrial practices and promoting sustainable development of the local community. As a key part of the company’s global network, the Singapore site will integrate closely with WuXi AppTec’s existing sites across Asia, Europe, and North America, offering effective CRDMO solutions for new drug R&D from discovery to commercialization with expanded flexibility and scalability.

Mr. Png Cheong Boon, Chairman of the Singapore Economic Development Board (EDB), said, "WuXi AppTec’s comprehensive CRDMO facility marks the company’s first foray into Singapore, and is a timely addition to Singapore’s thriving and growing pharmaceutical and biotechnology sector. With R&D and manufacturing activities housed under one roof, WuXi AppTec will be building a sizeable local team to drive the development of innovative therapeutics in Singapore to serve patients globally. Singapore remains committed to working with global healthcare partners to bring novel healthcare solutions to the rest of the world."

"We are thrilled to break ground on our long-planned site in Singapore. The progress we’ve made with many of our local partners is remarkable," said Dr. Minzhang Chen, Co-CEO of WuXi AppTec. "As we continue to enhance our capabilities and capacities to deliver high-quality solutions that meet the evolving needs of our customers, the new Singapore site will help us better serve our customers both locally and around the world."

"At WuXi AppTec, our vision is that one day every drug can be made and every disease can be treated," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "We are proud to work with like-minded partners in Singapore to carry out this vision for the global pharmaceutical and life sciences industry. With the enhanced capacity and capabilities we are building at this new Singapore site, we look forward to continuing to help our customers accelerate the development and commercialization of life-saving treatments and medicines for patients around the world."

The new Singapore site is projected to start operation in 2027 and will be built in different phases. The site is expected to bring approximately 1,600 employment opportunities once fully built.

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."